Xeris Biopharma Holdings Inc
F:2B30
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeris Biopharma Holdings Inc
F:2B30
|
US |
|
TuSimple Holdings Inc
OTC:TSPH
|
US |
|
Grupo Rotoplas SAB de CV
OTC:GRPRF
|
MX |
|
I
|
Ithaca Energy PLC
LSE:ITH
|
UK |
|
A
|
Associated British Foods PLC
F:AFO1
|
UK |
|
Ford Otomotiv Sanayi AS
F:FO9A
|
TR |
|
L
|
LyondellBasell Industries NV
SWB:DLY
|
UK |
|
Universal Insurance Holdings Inc
F:5UI
|
US |
Wall St Price Targets
2B30 Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for 2B30 is 11.504 EUR with a low forecast of 8.075 EUR and a high forecast of 18.888 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2B30's stock price target?
Price Target
11.504
EUR
According to Wall Street analysts, the average 1-year price target for 2B30 is 11.504 EUR with a low forecast of 8.075 EUR and a high forecast of 18.888 EUR.
What is the Revenue forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
10%
Over the last 8 years, the compound annual growth rate for Revenue has been 92%. The projected CAGR for the next 7 years is 10%.
What is the Gross Profit forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
20%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 88%. The projected CAGR for the next 5 years is 20%.
What is the Operating Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
63%
The compound annual growth rate for Operating Income over the next 5 years is 63%.
What is the Pre-Tax Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
517%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 517%.
What is the Net Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
356%
The compound annual growth rate for Net Income over the next 4 years is 356%.
